Literature DB >> 23897182

Survival rates in an unconventional haemodialysis strategy after a 10 year follow-up period.

Antonio Lozano-Díaz1, Beatriz Benavides-Almela, Pedro Quirós-Ganga, César Remón-Rodríguez.   

Abstract

BACKGROUND: At the end of the last century, level II scientific evidence supported higher survival rates for alternative haemodialysis (HD) techniques when compared with conventional HD, whose five-year life expectancy in Europe was below 40%. Our incident patients participated in an unconventional HD strategy from the year 2000, with the aim of assessing its influence on survival.
METHOD: A cohort study on 183 incident HD patients between 2000 and 2010. At the beginning of HD, we evaluated a history of cardiovascular disease (CVD) and Charlson index (ChI). In the year 2000, we began the unconventional HD strategy that included protocols of biocompatible high flux HD, dry weight target, a schedule of three weekly five hour sessions (HD 5h x 3) and from 2003, in combination with the foregoing, we began a schedule of four hour HD sessions on alternate days including weekends (every other day dialysis: EODD) for higher risk incident patients.
RESULTS: Of the 183 incident patients in the HD programme, 84 were dialysed in the 5hx3 HD schedule and 99 in EODD. The mean age was 60.6 ± 13.8 years, 31.7% were older than 70, 43% were diabetic, with CVD sufferers at 58.5% and the mean ChI was 4.55. Survival (%) from the first to the fifth year was 92, 82, 75, 62 and 55, with a median of 5.65 years (confidence interval [CI] 4.18-7.11) and a mean of 5.4 (CI 4.75-6.1).
CONCLUSIONS: The unconventional HD strategy that we applied to incident patients in the technique resulted in good survival.

Entities:  

Mesh:

Year:  2013        PMID: 23897182     DOI: 10.3265/Nefrologia.pre2013.Apr.11768

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  1 in total

1.  In-Center Hemodialysis: Time for a Paradigm Shift.

Authors:  Ambreen Gul; Dana C Miskulin; Antonia Harford; Philip Zager
Journal:  J Am Soc Nephrol       Date:  2018-09-05       Impact factor: 10.121

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.